Public Health Clinic–Based Hepatitis C Treatment
Amanda Rosecrans(Johns Hopkins University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Kathleen R. Page(Johns Hopkins University), Jaeson A. Smith(Baltimore City Health Department), Boatemaa Ntiri‐Reid(Maryland Department of Health), Aneesha Cheedalla(Johns Hopkins University), Karen E. Alston(Johns Hopkins University), Risha Irvin(Johns Hopkins University), Adena Greenbaum(Johns Hopkins University), Sarah T. Rives(Johns Hopkins University), Holly Brown(Johns Hopkins University), Robert E. Harris(The University of Texas at San Antonio Health Science Center), Lisa A. Scotti(Johns Hopkins University)
Cited by 6
Related Papers
Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15
|The Lancet Global Health|2018|1.2k
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
|Mycoses|2011|159
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
|UNC Libraries|2020|111